The TP73 complex network: Ready for clinical translation in cancer?

Genes Chromosomes and Cancer

Volumn 52, Issue 11, 2013, Pages 989-1006

  Soldevilla, Beatriz ^a   Millán, Coral San ^a   Bonilla, Félix ^a   Domínguez, Gemma ^a,b  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P53;

CANCER GENETICS; CARCINOGENESIS; GENE EXPRESSION; GENE TARGETING; GENETIC VARIABILITY; HUMAN; MOLECULAR INTERACTION; NONHUMAN; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TP73 GENE; TRANSLATIONAL RESEARCH;

EID: 84884699624     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22095     Document Type: Review

References (178)

1. Abusnina A, Alhosin M, Keravis T, Muller CD, Fuhrmann G, Bronner C, Lugnier C. 2011. Down-regulation of cyclic nucleotide phosphodiesterase PDE1A is the key event of p73 and UHRF1 deregulation in thymoquinone-induced acute lymphoblastic leukemia cell apoptosis. Cell Signal 23:152-160.
2. Achour M, Mousli M, Alhosin M, Ibrahim A, Peluso J, Muller CD, Schini-Kerth VB, Hamiche A, Dhe-Paganon S, Bronner C. 2013. Epigallocatechin-3-gallate up-regulates tumor suppressor gene expression via a reactive oxygen species-dependent down-regulation of UHRF1. Biochem Biophys Res Commun 430:208-212.
3. Agami R, Blandino G, Oren M, Shaul Y. 1999. Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature 399:809-813.
4. Agostini M, Tucci P, Killick R, Candi E, Sayan BS, Rivetti di Val Cervo P, Nicotera P, McKeon F, Knight RA, Mak TW, Melino G. 2011. Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proc Natl Acad Sci USA 108:21093-21098.
5. Al-Bahlani S, Fraser M, Wong AYC, Sayan BS, Bergeron R, Melino G, Tsang BK. 2011. P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism. Oncogene 30:4219-4230.
6. Alhosin M, Abusnina A, Achour M, Sharif T, Muller C, Peluso J, Chataigneau T, Lugnier C, Schini-Kerth VB, Bronner C, Fuhrmann G. 2010. Induction of apoptosis by thymoquinone in lymphoblastic leukemia Jurkat cells is mediated by a p73-dependent pathway which targets the epigenetic integrator UHRF1. Biochem Pharmacol 79:1251-1260.
7. Alhosin M, Ibrahim A, Boukhari A, Sharif T, Gies JP, Auger C, Schini-Kerth VB. 2012. Anti-neoplastic agent thymoquinone induces degradation of α and β tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts. Invest New Drugs 30:1813-1819.
8. Alla V, Kowtharapu BS, Engelmann D, Emmrich S, Schmitz U, Steder M, Pützer BM. 2012. E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle 11:3067-3078.
9. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK, 2007. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 26:3473-3481.
10. Aoki I, Higuchi M, Gotoh Y, 2012. NEDDylation controls the target specificity of E2F1 and apoptosis induction. Oncogene (in press).
11. Azmi AS, Aboukameel A, Banerjee S, Wang Z, Mohammad M, Wu J, Wang S, Yang D, Philip PA, Sarkar FH, Mohammad RM. 2010. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur J Cancer 46:1122-1131
12. Bálint, E, Bates S, Vousden K.H. 1999. Mdm2 binds p73 alpha without targeting degradation. Oncogene 18:3923-3929.
13. Becker K, Pancoska P, Concin N, Vanden Heuvel K, Slade N, Fischer M, Chalas E, Moll UM. 2006. Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers. Int J Oncol 29:889-902.
14. Bell HS, Ryan KM, 2008. iASPP inhibition: Increased options in targeting the p53 family for cancer therapy. Cancer Res 68:4959-4962.
15. Bell HS, Dufes C, O'Prey J, Crighton D, Bergamaschi D, Lu X, Schätzlein AG, Vousden KH, Ryan KM. 2007. A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J Clin Invest 117:1008-1018.
16. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T. 2003. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3:387-402.
17. Bergamaschi, D, Samuels Y, Jin B, Duraisingham S, Crook T, Lu X. 2004. ASPP1 and ASPP2: Common activators of p53 family members. Mol Cell Biol 24:1341-1350.
18. Bernassola F, Salomoni P, Oberst A, Di Como CJ, Pagano M, Melino G, Pandolfi PP. 2004. Ubiquitin-dependent degradation of p73 is inhibited by PML. J Exp Med 199:1545-1557.
19. Boominathan L. 2010. The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network. Cancer Metastasis Rev 29:613-639.
20. Cai Y, Qiu S, Gao X, Gu SZ, Liu ZJ. 2012. iASPP inhibits p53-independent apoptosis by inhibiting transcriptional activity of p63/p73 on promoters of proapoptotic genes. Apoptosis 17:777-783.
21. Cam H, Griesmann H, Beitzinger M, Hofmann L, Beinoraviciute-Kellner R, Sauer M, Hüttinger-Kirchhof N, Oswald C, Friedl P, Gattenlöhner S, Burek C, Rosenwald A, Stiewe T. 2006. p53 family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell 10:281-293.
22. Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G, Ponzoni M, Tonini GP, Romani M. 2002. Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 9:246-251.
23. Castellino RC, De Bortoli M, Lin LL, Skapura DG, Rajan JA, Adesina AM, Perlaky L, Irwin MS, Kim JYH. 2007. Overexpressed TP73 induces apoptosis in medulloblastoma. BMC Cancer 7:127.
24. Chen YK, Huse SS, Lin LM. 2003. Differential expression of p53, p63 and p73 proteins in human buccal squamous-cell carcinomas. Clin Otolaryngol Allied Sci 28:451-455.
25. Choi HR, Batsakis JG, Zhan F, Sturgis E, Luna MA, El-Naggar AK. 2002. Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Hum Pathol 33:158-164.
26. Coates PJ. 2006. Regulating p73 isoforms in human tumours. J Pathol 210:385-389.
27. Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H, Daxenbichler G, Zeimet A, Zeillinger R, Marth C, Moll UM. 2004. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 64:2449-2460.
28. Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R, Tong D, Schuster E, Hefler L, Heim K, Mueller-Holzner E, Marth C, Moll UM, Zeimet AG, Zeillinger R. 2005. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: Evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res 11:8372-8383.
29. Dar AA, Belkhiri A, Ecsedy J, Zaika A, El-Rifai W. 2008. Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res 68:8998-9004.
30. De Thé H, Chen Z. 2010. Acute promyelocytic leukaemia: Novel insights into the mechanisms of cure. Nat Rev Cancer 10:775-783.
31. Díaz R, Peña C, Silva J, Lorenzo Y, García V, García JM, Sánchez A, Espinos P, Yuste R, Bonilla F, Domínguez G. 2008. p73 Isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis. Int J Cancer 123:1060-1067.
32. Díaz R, González-Sancho JM, Soldevilla B, Silva J, García JM, García V, Peña C, Herrera M, Gómez I, Bonilla F, Domínguez G. 2010. Differential regulation of TP73 isoforms by 1α, 25-dihydroxyvitamin D3 and survivin in human colon and breast carcinomas. Genes Chromosomes Cancer 49:1135-1142.
33. Domínguez G, García JM, Peña C, Silva J, García V, Martínez L, Maximiano C, Gómez ME, Rivera JA, García-Andrade C, Bonilla F. 2006. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: Putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol 24:805-815.
34. Dulloo I, Gopalan G, Melino G, Sabapathy K. 2010. The antiapoptotic DeltaNp73 is degraded in a c-Jun-dependent manner upon genotoxic stress through the antizyme-mediated pathway. Proc Natl Acad Sci USA 107:4902-4907.
35. Farhang Ghahremani M, Goossens S, Haigh JJ. 2013. The p53 family and VEGF regulation: "It's complicated". Cell Cycle 12:1331-1332.
36. Faridoni-Laurens L, Bosq J, Janot F, Vayssade M, Le Bihan ML, Kaghad M, Caput D, Bénard J, Ahomadegbe JC. 2001. P73 expression in basal layers of head and neck squamous epithelium: A role in differentiation and carcinogenesis in concert with p53 and p63? Oncogene 20:5302-5312.
37. Faridoni-Laurens L, Tourpin S, Alsafadi S, Barrois M, Temam S, Janot F, Koscielny S, Bosq J, Bénard J, Ahomadegbe JC. 2008. Involvement of N-terminally truncated variants of p73, deltaTAp73, in head and neck squamous cell cancer: A comparison with p53 mutations. Cell Cycle 7:1587-1596.
38. Ferru A, Denis S, Guilhot J, Gibelin H, Tourani JM, Kraimps JL, Larsen CJ, Karayan-Tapon L. 2006. Expression of TAp73 and DeltaNp73 isoform transcripts in thyroid tumours. Eur J Surg Oncol 32:228-230.
39. Fillippovich I, Sorokina N, Gatei M, Haupt Y, Hobson K, Moallem E, Spring K, Mould M, McGuckin MA, Lavin MF, Khanna KK. 2001. Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53. Oncogene 20:514-522.
40. Fontemaggi G, Gurtner A, Strano S, Higashi Y, Sacchi A, Piaggio G, Blandino G. 2001. The transcriptional repressor ZEB regulates p73 expression at the crossroad between proliferation and differentiation. Mol Cell Biol 21:8461-8470.
41. Gaiddon C, Lokshin M, Gross I, Levasseur D, Taya Y, Loeffler JP, Prives C. 2003. Cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle-dependent manner and negatively regulate p73. J Biol Chem 278:27421-27431.
42. Ghaffari SH, Momeny M, Bashash D, Mirzaei R, Ghavamzadeh A, Alimoghaddam K. 2012. Cytotoxic effect of arsenic trioxide on acute promyelocytic leukemia cells through suppression of NFkβ-dependent induction of hTERT due to down-regulation of Pin1 transcription. Hematology 17:198-206.
43. Gong JG, Costanzo A, Yang HQ, Melino G, Kaelin WG, Jr Levrero M, Wang JY. 1999. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399:806-809.
44. Gonzalez S, Perez-Perez MM, Hernando E, Serrano M, Cordon-Cardo C. 2005. p73beta-Mediated apoptosis requires p57kip2 induction and IEX-1 inhibition. Cancer Res 65:2186-2192.
45. Grob TJ, Novak U, Maisse C, Barcaroli D, Lüthi AU, Pirnia F, Hügli B, Graber HU, De Laurenzi V, Fey MF, Melino G, Tobler A. 2001. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ 8:1213-1223.
46. Guan M, Chen Y. 2005. Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: Correlation with Gleason score. J Clin Pathol 58:1175-1179.
47. Guida E, Bisso A, Fenollar-Ferrer C, Napoli M, Anselmi C, Girardini JE, Carloni P, Del Sal G. 2008. Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells. Cancer Res 68:6550-6558.
48. Harms K, Nozell S, Chen X. 2004. The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci 61:822-842.
49. He M, Liu Y, Deng X, Qi S, Sun X, Liu G, Yongguang L, Zhao M. 2013. Down-regulation of miR-200b-3p by low p73 contributes to the androgen-independence of prostate cancer cells. Prostate 73:1048-1056.
50. Herreros-Villanueva M, Muñiz P, García-Girón C, Cavia-Saiz M, del Corral MJC. 2010. TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status. J Transl Med 8:15.
51. Hong SM, Cho H, Moskaluk CA, Yu E, Zaika AI. 2007. p63 and p73 expression in extrahepatic bile duct carcinoma and their clinical significance. J Mol Histol 38:167-175.
52. Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, Flores ER, Tsai KY, Jacks T, Vousden KH, Kaelin WG Jr. 2000. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407:645-648.
53. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S, 2002. Possible oncogenic potential of DeltaNp73: A newly identified isoform of human p73. Cancer Res. 62:636-641.
54. Ito Y, Takeda T, Wakasa K, Tsujimoto M, Sakon M, Matsuura N. 2001. Expression of p73 and p63 proteins in pancreatic adenocarcinoma: p73 Overexpression is inversely correlated with biological aggressiveness. Int J Mol Med 8:67-71.
55. Ito Y, Uramoto H, Funa K, Yoshida H, Jikuzono T, Asahi S, Higashiyama T, Tomoda C, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A. 2006. Delta Np73 expression in thyroid neoplasms originating from follicular cells. Pathology 38:205-209.
56. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. 2011. Global cancer statistics. CA Cancer J Clin 61:69-90.
57. Jones EV, Dickman MJ, Whitmarsh, AJ.2007. Regulation of p73-mediated apoptosis by c-Jun N-terminal kinase. Biochem J 405:617-623.
58. Jørgensen A, Blomberg Jensen M, Nielsen JE, Juul A, Rajpert-De Meyts E. 2012. Influence of vitamin D on cisplatin sensitivity in testicular germ cell cancer-derived cell lines and in a NTera2 xenograft model. J Steroid Biochem Mol Biol 136:238-246.
59. Jost CA, Marin MC, Kaelin WG Jr. 1997. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 389:191-194.
60. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809-819.
61. Kartasheva NN, Lenz-Bauer C, Hartmann O, Schäfer H, Eilers M, Dobbelstein M. 2003. DeltaNp73 can modulate the expression of various genes in a p53-independent fashion. Oncogene 22:8246-8254.
62. Katayama H, Wang J, Treekitkarnmongkol W, Kawai H, Sasai K, Zhang H, Wang H, Adams HP, Jiang S, Chakraborty SN, Suzuki F, Arlinghaus RB, Liu J, Mobley JA, Grizzle WE, Wang Hu, Sen S. 2012. Aurora kinase-A inactivates DNA damage-induced apoptosis and spindle assembly checkpoint response functions of p73. Cancer Cell 21:196-211.
63. Kenzelmann BD, Spano MS, Bieging KT, Jiang D, Dusek RL, Brady CA, Sidow, A, Attardi LD. 2013. Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses. Genes Dev 27:1016-1031.
64. Kilic E, Brüggenwirth HT, Meier M, Naus NC, Beverloo HB, Meijerink JP, Luyten GP, de Klein A. 2008. Increased expression of p73Deltaex2 transcript in uveal melanoma with loss of chromosome 1p. Melanoma Res 18:208-213.
65. Killick R, Niklison-Chirou M, Tomasini R, Bano D, Rufini A, Grespi F, Velletri T, Tucci P, Sayan BS, Conforti F, Gallagher E, Nicotera P, Mak TW, Melino G, Knight RA, Agostini M. 2011. p73: A multifunctional protein in neurobiology. Mol Neurobiol 43:139-146.
66. Knouf EC, Garg K, Arroyo JD, Correa Y, Sarkar D, Parkin RK, Wurz K, O'Briant KC, Godwin AK, Urban ND, Ruzzo WL, Gentleman R, Drescher CW, Swisher EM, Tewari M. 2012. An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription. Nucleic Acids Res 40:499-510.
67. Kommagani R, Whitlatch A, Leonard MK, Kadakia MP. 2010. p73 is essential for vitamin D-mediated osteoblastic differentiation. Cell Death Differ 17:398-407.
68. Kontaki H, Talianidis I. 2010. Lysine methylation regulates E2F1-induced cell death. Mol. Cell 39:152-160.
69. Kravchenko JE, Ilyinskaya GV, Komarov PG, Agapova LS, Kochetkov DV, Strom E, Frolova EI, Kovriga I, Gudkov AV, Feinstein E, Chumakov PM. 2008. Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc Natl Acad Sci USA 105:6302-6307.
70. Kubo N, Okoshi R, Nakashima K, Shimozato O, Nakagawara A, Ozaki T. 2010. MDM2 promotes the proteasomal degradation of p73 through the interaction with Itch in HeLa cells. Biochem Biophys Res Commun 403:405-411.
71. Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV, Blum KA, Blum W, Ramanunni A, Raymond CA, Smith LL, Lehman A, Mo X, Jarjoura D, Chen CS, Ford R Jr, Rader C, Muthusamy N, Johnson AJ, Byrd JC. 2010. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 115:2619-2629.
72. Lau LMS, Wolter JK, Lau JTML, Cheng LS, Smith KM, Hansford LM, Zhang L, Baruchel S, Robinson F, Irwin MS. 2009. Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma. Oncogene 28:2024-2033.
73. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. 2007. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 117:1370-1380.
74. Leung THY, Ngan HYS. 2010. Interaction of TAp73 and breast cancer-associated gene 3 enhances the sensitivity of cervical cancer cells in response to irradiation-induced apoptosis. Cancer Res 70:6486-6496.
75. Leupin N, Lüthi A, Novak U, Grob TJ, Hügli B, Graber H, Fey MF, Tobler A. 2004. P73 status in B-cell chronic lymphocytic leukaemia. Leuk. Lymphoma 45:1205-1207.
76. Lin YL, Sengupta S, Gurdziel K, Bell GW, Jacks T, Flores ER. 2009. p63 and p73 transcriptionally regulate genes involved in DNA repair. PLoS Genet 5:e1000680.
77. Lin Y, Cheng Z, Yang Z, Zheng J, Lin T. 2012. DNp73 improves generation efficiency of human induced pluripotent stem cells. BMC Cell Biol 13:9.
78. Liu SS, Chan KYK, Cheung ANY, Liao XY, Leung TW, Ngan HYS. 2006. Expression of deltaNp73 and TAp73alpha independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. Clin Cancer Res 12:3922-3927.
79. Liu K, Ling S, Lin WC. 2011. TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73. Mol Cell Biol 31:4464-4481.
80. Lo Iacono M, Monica V, Saviozzi S, Ceppi P, Bracco E, Papotti M, Scagliotti GV. 2011. p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue. J Thorac Oncol 6:473-481.
81. Logotheti S, Michalopoulos I, Sideridou M, Daskalos A, Kossida S, Spandidos DA, Field JK, Vojtesek B, Liloglou T, Gorgoulis V, Zoumpourlis V. 2010. Sp1 binds to the external promoter of the p73 gene and induces the expression of TAp73gamma in lung cancer. FEBS J 277:3014-3027.
82. Lunghi P, Costanzo A, Levrero M, Bonati A. 2004. Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells. Blood 104:519-525.
83. Lunghi P, Costanzo A, Salvatore L, Noguera N, Mazzera L, Tabilio A, Lo-Coco, F, Levrero M, Bonati A. 2006. MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis. Blood 107:4549-4553.
84. Lunghi P, Giuliani N, Mazzera L, Lombardi G, Ricca M, Corradi A, Cantoni AM, Salvatore L, Riccioni R, Costanzo A, Testa U, Levrero M, Rizzoli V, Bonati A. 2008. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood 112:2450-2462.
85. Ma Y, Yu WD, Hershberger PA, Flynn G, Kong RX, Trump DL, Johnson CS. 2008. 1alpha, 25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model. Mol Cancer Ther 7:3047-3055.
86. Ma Y, Yu WD, Trump DL, Johnson CS. 2010. 1, 25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer 116:3294-3303.
87. Maddocks ODK, Vousden KH. 2011. Metabolic regulation by p53. J Mol Med 89:237-245.
88. Maisse C, Munarriz E, Barcaroli D, Melino G, De Laurenzi V. 2004. DNA damage induces the rapid and selective degradation of the DeltaNp73 isoform, #allowing apoptosis to occur. Cell Death Differ 11:685-687.
89. Mancini M, Corradi V, Petta S, Barbieri E, Manetti F, Botta M, Santucci MA. 2011. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib. J Pharmacol Exp Ther 336:596-604.
90. Mantovani F, Piazza S, Gostissa M, Strano S, Zacchi P, Mantovani R, Blandino G, Del Sal G. 2004. Pin1 links the activities of c-Abl and p300 in regulating p73 function. Mol Cell 14:625-636.
91. Meier M, den Boer ML, Meijerink JPP, Broekhuis MJC, Passier MMCJ, van Wering ER, Janka-Schaub GE, Pieters R. 2006. Differential expression of p73 isoforms in relation to drug resistance in childhood T-lineage acute lymphoblastic leukaemia. Leukemia 20:1377-1384.
92. Melino G, De Laurenzi V, Vousden KH. 2002. p73: Friend or foe in tumorigenesis. Nat Rev Cancer 2:605-615.
93. Merlo P, Fulco M, Costanzo A, Mangiacasale R, Strano S, Blandino G, Taya Y, Lavia P, Levrero M. 2005. A role of p73 in mitotic exit. J Biol Chem 280:30354-30360.
94. Messina RL, Sanfilippo M, Vella V, Pandini G, Vigneri P, Nicolosi ML, Gianì F, Vigneri R, Frasca F. 2012. Reactivation of p53 mutants by prima-1 [corrected] in thyroid cancer cells. Int J Cancer 130:2259-2270.
95. Müller M, Schilling T, Sayan AE, Kairat A, Lorenz K, Schulze-Bergkamen H, Oren M, Koch A, Tannapfel A, Stremmel W, Melino G, Krammer PH. 2005. TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 12:1564-1577.
96. Niemantsverdriet M, Nagle P, Chiu RK, Langendijk JA, Kampinga HH, Coppes RP. 2012. ΔNp73 enhances promoter activity of TGF-β induced genes. PLoS ONE 7:e50815.
97. Nyman U, Vlachos P, Cascante A, Hermanson O, Zhivotovsky B, Joseph B. 2009. Protein kinase C-dependent phosphorylation regulates the cell cycle-inhibitory function of the p73 carboxy terminus transactivation domain. Mol Cell Biol 29:1814-1825.
98. O'Nions J, Brooks LA, Sullivan A, Bell A, Dunne B, Rozycka M, Reddy A, Tidy JA, Evans D, Farrell PJ, Evans A, Gasco M, Gusterson B, Crook T. 2001. p73 is over-expressed in vulval cancer principally as the Delta 2 isoform. Br J Cancer 85:1551-1556.
99. Oberst A, Rossi M, Salomoni P, Pandolfi PP, Oren M, Melino G, Bernassola F. 2005. Regulation of the p73 protein stability and degradation. Biochem Biophys Res Commun 331:707-712.
100. Olivier M, Petitjean A, Marcel V, Pétré A, Mounawar M, Plymoth A, de Fromentel CC, Hainaut P. 2009. Recent advances in p53 research: An interdisciplinary perspective. Cancer Gene Ther 16:1-12.
101. Onoda C, Kuribayashi K, Nirasawa S, Tsuji N, Tanaka M, Kobayashi D, Watanabe N. 2011. (-)-Epigallocatechin-3-gallate induces apoptosis in gastric cancer cell lines by down-regulating survivin expression. Int J Oncol 38:1403-1408.
102. Ott S, Geiser T. 2012. [Epidemiology of lung tumors]. Ther Umsch 69:381-388.
103. Park HR, Kim YW, Park JH, Maeng YH, Nojima T, Hashimoto H, Park YK. 2004. Low expression of p63 and p73 in osteosarcoma. Tumori 90:239-243.
104. Patel S, George R, Autore F, Fraternali F, Ladbury JE, Nikolova PV. 2008. Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax. Nucleic Acids Res 36:5139-5151.
105. Pediconi N, Guerrieri F, Vossio S, Bruno T, Belloni L, Schinzari V, Scisciani C, Fanciulli M, Levrero M. 2009. hSirT1-dependent regulation of the PCAF-E2F1-p73 apoptotic pathway in response to DNA damage. Mol Cell Biol 29:1989-1998.
106. Peirce SK, Findley HW. 2009. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73. Int J Oncol 34:1395-1402.
107. Petrenko O, Zaika A, Moll UM. 2003. deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell Biol 23:5540-5555.
108. Pipaon C, Real PJ, Fernandez-Luna JL. 2005. Defective binding of transcriptional repressor ZEB via DNA methylation contributes to increased constitutive levels of p73 in Fanconi anemia cells. FEBS Lett 579:4610-4614.
109. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD. 2000. An anti-apoptotic role for the p53 family |member, p73, during developmental neuron death. Science 289:304-306.
110. Puig P, Capodieci P, Drobnjak M, Verbel D, Prives C, Cordon-Cardo C, Di Como, CJ. 2003. p73 Expression in human normal and tumor tissues: Loss of p73alpha expression is associated with tumor progression in bladder cancer. Clin Cancer Res 9:5642-5651.
111. Puppin C, Passon N, Frasca F, Vigneri R, Tomay F, Tomaciello S, Damante G. 2011. In thyroid cancer cell lines expression of periostin gene is controlled by p73 and is not related to epigenetic marks of active transcription. Cell Oncol (Dordr) 34:131-140.
112. Ramadan S, Terrinoni A, Catani MV, Sayan AE, Knight RA, Mueller M, Krammer PH, Melino G, Candi E. 2005. p73 induces apoptosis by different mechanisms. Biochem Biophys Res Commun 331:713-717.
113. Ray R.M, Bhattacharya S, Johnson LR. 2011. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1. Apoptosis 16:35-44.
114. Remke M, Hielscher T, Northcott PA, Witt H, Ryzhova M, Wittmann A, Benner A, von Deimling A, Scheurlen W, Perry A, Croul S, Kulozik AE, Lichter P, Taylor MD, Pfister SM, Korshunov A. 2011. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol 29:2717-2723.
115. Rizzo MG, Giombini E, Diverio D, Vignetti M, Sacchi A, Testa U, Lo-Coco F, Blandino G. 2004. Analysis of p73 expression pattern in acute myeloid leukemias: Lack of DeltaN-p73 expression is a frequent feature of acute promyelocytic leukemia. Leukemia 18:1804-1809.
116. Robinson RA, Lu X, Jones EY, Siebold C. 2008. Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73. Structure 16:259-268.
117. Rökaeus N, Shen J, Eckhardt I, Bykov VJN, Wiman KG, Wilhelm MT. 2010. PRIMA-1(MET)/APR-246 targets mutant forms of p53 family members p63 and p73. Oncogene 29:6442-6451.
118. Romani M, Scaruffi P, Casciano I, Mazzocco K, Lo Cunsolo C, Cavazzana A, Gambini C, Boni L, De Bernardi B, Tonini GP. 1999. Stage-independent expression and genetic analysis of tp73 in neuroblastoma. Int J Cancer 84:365-369.
119. Rosenbluth JM, Mays DJ, Pino MF, Tang LJ, Pietenpol JA. 2008. A gene signature-based approach identifies mTOR as a regulator of p73. Mol Cell Biol 28:5951-5964.
120. Rossi M, Sayan AE, Terrinoni A, Melino G, Knight RA. 2004. Mechanism of induction of apoptosis by p73 and its relevance to neuroblastoma biology. Ann NY Acad Sci 1028:143-149.
121. Rossi M, De Laurenzi V, Munarriz E, Green DR, Liu YC., Vousden KH, Cesareni G, Melino G. 2005. The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J 24:836-848.
122. Rufini A, Agostini M, Grespi F, Tomasini R, Sayan BS, Niklison-Chirou MV, Conforti F, Velletri T, Mastino A, Mak TW, Melino G, Knight RA. 2011. p73 in Cancer. Genes Cancer 2:491-502.
123. Sampath D, Calin GA, Puduvalli VK, Gopisetty G, Taccioli C, Liu CG, Ewald B, Liu C, Keating MJ, Plunkett W. 2009. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood 113:3744-3753.
124. Sanchez-Prieto R, Sanchez-Arevalo VJ, Servitja JM, Gutkind JS. 2002. Regulation of p73 by c-Abl through the p38 MAP kinase pathway. Oncogene 21:974-979.
125. Sang M, Li Y, Ozaki T, Ono S, Ando K, Yamamoto H, Koda T, Geng C, Nakagawara A. 2006. p73-dependent induction of 14-3-3sigma increases the chemo-sensitivity of drug-resistant human breast cancers. Biochem Biophys Res Commun 347:327-333.
126. Sang M, Ando K, Okoshi R, Koida N, Li Y, Zhu Y, Shimozato O, Geng C, Shan B, Nakagawara A, Ozaki T. 2009. Plk3 inhibits pro-apoptotic activity of p73 through physical interaction and phosphorylation. Genes Cells 14:775-788.
127. Sasaki Y, Mita H, Toyota M, Ishida S, Morimoto I, Yamashita T, Tanaka T, Imai K, Nakamura Y, Tokino T. 2003. Identification of the interleukin 4 receptor alpha gene as a direct target for p73. Cancer Res 63:8145-8152.
128. Sayan BS, Yang AL, Conforti F, Tucci P, Piro MC, Browne GJ, Agostini M, Bernardini S, Knight RA, Mak TW, Melino G. 2010. Differential control of TAp73 and DeltaNp73 protein stability by the ring finger ubiquitin ligase PIR2. Proc Natl Acad Sci USA 107:12877-12882.
129. Scian MJ, Carchman EH, Mohanraj L, Stagliano KER, Anderson MAE, Deb D, Crane BM, Kiyono T, Windle B, Deb SP, Deb S. 2008. Wild-type p53 and p73 negatively regulate expression of proliferation related genes. Oncogene 27:2583-2593.
130. Seelan RS, Irwin M, van der Stoop P, Qian C, Kaelin WG Jr, Liu W. 2002. The human p73 promoter: Characterization and identification of functional E2F binding sites. Neoplasia 4:195-203.
131. Shammas MA, Neri P, Koley H, Batchu RB, Bertheau RC, Munshi V, Prabhala R, Fulciniti M, Tai YT, Treon SP, Goyal RK, Anderson KC, Munshi NC. 2006. Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: Biologic activity and therapeutic implications. Blood 108:2804-2810.
132. Sharif T, Auger C, Alhosin M, Ebel C, Achour M, Etienne-Selloum N, Fuhrmann G, Bronner C, Schini-Kerth VB. 2010. Red wine polyphenols cause growth inhibition and apoptosis in acute lymphoblastic leukaemia cells by inducing a redox-sensitive up-regulation of p73 and down-regulation of UHRF1. Eur J Cancer 46:983-994.
133. Sherr CJ, Weber JD. 2000. The ARF/p53 pathway. Curr Opin Genet Dev 10:94-99.
134. Soldevilla B, Díaz R, Silva J, Campos-Martín Y, Muñoz C, García V, García JM, Peña C, Herrera M, Rodriguez M, Gómez I, Mohamed N, Marques MM, Bonilla F, Domínguez, G. 2011. Prognostic impact of ΔTAp73 isoform levels and their target genes in colon cancer patients. Clin Cancer Res 17:6029-6039.
135. Song S, Choi K, Ryu SW, Kang, SW, Choi C. 2011. TRAIL promotes caspase-dependent pro-inflammatory responses via PKCδ activation by vascular smooth muscle cells. Cell Death Dis 2:e223.
136. Stiewe T, Pützer BM. 2000. Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 26:464-469.
137. Stiewe T, Theseling CC, Pützer BM. 2002a. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: Implications for tumorigenesis. J Biol Chem 277:14177-14185.
138. Stiewe T, Zimmermann S, Frilling A, Esche H, Pützer BM. 2002b. Transactivation-deficient DeltaTA-p73 acts as an oncogene. Cancer Res 62:3598-3602.
139. Stiewe T, Stanelle J, Theseling CC, Pollmeier B, Beitzinger M, Pützer BM. 2003. Inactivation of retinoblastoma (RB) tumor suppressor by oncogenic isoforms of the p53 family member p73. J Biol Chem 278:14230-14236.
140. Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A, Oren M, Sudol M, Cesareni G, Blandino G. 2001. Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 276:15164-15173.
141. Sullivan A, Lu X. 2007. ASPP: A new family of oncogenes and tumour suppressor genes. Br J Cancer 96:196-200.
142. Sun XF. 2002. p73 overexpression is a prognostic factor in patients with colorectal adenocarcinoma. Clin Cancer Res 8:165-170.
143. Tabe Y, Sebasigari D, Jin L, Rudelius M, Davies-Hill T, Miyake K, Miida T, Pittaluga S, Raffeld M. 2009. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin Cancer Res 15:933-942.
144. Takahashi H, Ichimiya S, Nimura Y, Watanabe M, Furusato M, Wakui S, Yatani R, Aizawa S, Nakagawara A. 1998. Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res 58:2076-2077.
145. Tiwary R, Yu W, Sanders BG, Kline K. 2011. α-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73. Breast Cancer Res 13:R1.
146. Toh WH, Siddique MM, Boominathan L, Lin KW, Sabapathy K. 2004. c-Jun regulates the stability and activity of the p53 homologue, p73. J Biol Chem 279:44713-44722.
147. Tomasini R, Tsuchihara K, Wilhelm M, Fujitani M, Rufini A, Cheung CC, Khan F, Itie-Youten A, Wakeham A, Tsao MS, Iovanna JL, Squire J, Jurisica I, Kaplan D, Melino G, Jurisicova A, Mak TW. 2008. TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev 22:2677-2691.
148. Tomasini R, Tsuchihara K, Tsuda C, Lau SK, Wilhelm M, Ruffini A, Tsao M, Iovanna JL, Jurisicova A, Melino G, Mak TW. 2009. TAp73 regulates the spindle assembly checkpoint by modulating BubR1 activity. Proc Natl Acad Sci USA 106:797-802.
149. Tomlinson V, Gudmundsdottir K, Luong P, Leung KY, Knebel A, Basu S. 2010. JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis. Cell Death Dis 1:e29.
150. Toumi AA, El Hadj OEA, Ben Mahmoud LK, Ben Hmida AEM, Chaar I, Gharbi L, Mzabi S, Bouraoui S. 2010. The prognostic value of p73 overexpression in colorectal carcinoma: A clinicopathologic, immunohistochemical, and statistical study of 204 patients. Appl Immunohistochem Mol Morphol 18:128-136.
151. Tsai KKC, Yuan ZM. 2003. c-Abl stabilizes p73 by a phosphorylation-augmented interaction. Cancer Res 63:3418-3424.
152. Tuve S, Wagner SN, Schittek B, Pützer BM. 2004. Alterations of DeltaTA-p 73 splice transcripts during melanoma development and progression. Int J Cancer 108:162-166.
153. Udayakumar T, Shareef MM, Diaz DA, Ahmed MM, Pollack A. 2010. The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: Understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy. Semin Radiat Oncol 20:258-266.
154. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Morita M, Funa K, Yasumoto K. 2004. Expression of deltaNp73 predicts poor prognosis in lung cancer. Clin Cancer Res 10:6905-6911.
155. Urist M, Prives C. 2004. The linchpin? Pin1 meets p73. Cancer Cell 5:515-517.
156. Urist M, Tanaka T, Poyurovsky MV, Prives C. 2004. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev 18:3041-3054.
157. Vella V, Puppin C, Damante G, Vigneri R, Sanfilippo M, Vigneri P, Tell G, Frasca F. 2009. DeltaNp73alpha inhibits PTEN expression in thyroid cancer cells. Int J Cancer 124:2539-2548.
158. Vilgelm A, Wei JX, Piazuelo MB, Washington MK, Prassolov V, El-Rifai W, Zaika A. 2008. DeltaNp73alpha regulates MDR1 expression by inhibiting p53 function. Oncogene 27:2170-2176.
159. Vilgelm AE, Hong SM, Washington MK, Wei J, Chen H, El-Rifai W, Zaika A. 2010. Characterization of ΔNp73 expression and regulation in gastric and esophageal tumors. Oncogene 29:5861-5868.
160. Wager M, Guilhot J, Blanc JL, Ferrand S, Milin S, Bataille B, Lapierre F, Denis S, Chantereau T, Larsen CJ, Karayan-Tapon L. 2006. Prognostic value of increase in transcript levels of Tp73 DeltaEx2-3 isoforms in low-grade glioma patients. Br J Cancer 95:1062-1069.
161. Wang JY. 2000. Regulation of cell death by the Abl tyrosine kinase. Oncogene 19:5643-5650.
162. Wang XH, O'Connor D, Brimmell M, Packham G. 2009. The BAG-1 cochaperone is a negative regulator of p73-dependent transcription. Br J Cancer 100:1347-1357.
163. Wang X, Zeng L, Wang J, Chau JFL, Lai KP, Jia D, Poonepalli A, Hande MP, Liu H, He G, He L, Li B. 2011. A positive role for c-Abl in Atm and Atr activation in DNA damage response. Cell Death Differ 18:5-15.
164. Wang Y, He X, Yu Q, Eng C. 2013. Androgen receptor-induced tumor suppressor, KLLN, inhibits breast cancer growth and transcriptionally activates p53/p73-mediated apoptosis in breast carcinomas. Hum Mol Genet 22:2263-2272
165. Watson IR, Blanch A, Lin DCC, Ohh M, Irwin MS. 2006. Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function. J Biol Chem 281:34096-34103.
166. Weber A, Bellmann U, Bootz F, Wittekind C, Tannapfel A. 2002. Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck. Int J Cancer 99:22-28.
167. Wilhelm MT, Rufini A, Wetzel MK, Tsuchihara K, Inoue S, Tomasini R, Itie-Youten A, Wakeham A, Arsenian-Henriksson M, Melino G, Kaplan DR, Miller FD, Mak TW. 2010. Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev 24:549-560.
168. Wong SW, Tiong KH, Kong WY, Yue YC, Chua CH, Lim JY, Lee CY, Quah SI, Fow C, Chung C, So I, Tan BS, Choo HL, Rosli R, Cheong SK, Leong CO. 2011. Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73. Breast Cancer Res Treat 128:301-313.
169. Woo CC, Kumar AP, Sethi G, Tan KHB. 2012. Thymoquinone: Potential cure for inflammatory disorders and cancer. Biochem Pharmacol 83:443-451.
170. Wu S, Murai S, Kataoka K, Miyagishi M. 2008. Yin Yang 1 induces transcriptional activity of p73 through cooperation with E2F1. Biochem Biophys Res Commun 365:75-81.
171. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F, Caput D. 2000. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404:99-103.
172. Yokomizo A, Mai M, Bostwick DG, Tindall DJ, Qian J, Cheng L, Jenkins RB, Smith DI, Liu W. 1999. Mutation and expression analysis of the p73 gene in prostate cancer. Prostate 39:94-100.
173. Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY, Lu H, Kharbanda S, Weichselbaum R, Kufe D.1999. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 399:814-817.
174. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E, Moll UM. 2002. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 196:765-780.
175. Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X, Kaelin WG, Jr., Oren M, Chen J, Lu H. 1999. MDM2 suppresses p73 function without promoting p73 degradation. Mol Cell Biol 19:3257-3266.
176. Zhang P, Liu SS, Ngan HYS. 2012. TAp73-mediated the activation of c-Jun N-terminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells. PLoS One 7:e42985.
177. Zheng T, Wang J, Song X, Meng X, Pan S, Jiang H, Liu L. 2010. Nutlin-3 cooperates with doxorubicin to induce apoptosis of human hepatocellular carcinoma cells through p53 or p73 signaling pathways. J Cancer Res Clin Oncol 136:1597-1604.
178. Zitterbart K, Zavrelova I, Kadlecova J, Spesna R, Kratochvilova A, Pavelka Z, Sterba J. 2007. p73 expression in medulloblastoma: TAp73/DeltaNp73 transcript detection and possible association of p73alpha/DeltaNp73 immunoreactivity with survival. Acta Neuropathol 114:641-650.